METiS TechBio, the World's First Publicly Listed AI-Powered Drug Delivery Company, Debuts on the Hong Kong Stock Exchange, "The SpaceX of Pharmaceuticals" Ushers in a New Era of Biopharmaceuticals

May 13, 2026, METiS TechBio (7666.HK) has successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange, raising approximately HKD 2.1 billion (USD 2.7 billion) and marking a significant milestone as the world's first publicly listed AI-powered drug delivery company. This IPO is notable for being the largest healthcare fundraising in Hong Kong for the year 2026, with the public offering being oversubscribed by more than 6,900 times, reflecting strong investor interest and confidence in the biopharmaceutical sector.

Founded just six years ago, METiS TechBio has rapidly emerged as a leader in the AI-driven biopharmaceutical landscape, positioning itself as the "SpaceX of pharmaceuticals." The company specializes in AI-powered nanodelivery systems, leveraging its proprietary platform, NanoForge, which integrates advanced AI technologies with biopharmaceutical development. This innovative approach enables the company to streamline drug development processes, enhance drug efficacy, and target delivery to specific organs and tissues, thereby addressing significant unmet medical needs across various disease areas, including oncology and immunology.

The IPO attracted a diverse array of cornerstone investors, including major global asset managers such as BlackRock, which led the subscription with a USD 50 million investment. Other notable participants included UBS Asset Management Singapore, Mirae Asset, and ORIX Corporation, along with several specialized healthcare and technology funds. The overwhelming demand for shares, evidenced by the high oversubscription rates, underscores the growing recognition of AI-driven biopharmaceutical technologies as critical components of future healthcare innovations.

The successful listing of METiS TechBio comes at a time when the biopharmaceutical sector is increasingly focused on integrating artificial intelligence into drug development. As the industry grapples with challenges such as rising R&D costs and lengthy development timelines, AI technologies offer the potential to revolutionize traditional processes. The strong backing from institutional investors reflects a broader trend of increasing investment in AI-driven healthcare solutions, which are viewed as essential for advancing medical research and improving patient outcomes.

Looking ahead, METiS TechBio's IPO not only sets a precedent for future AI-focused listings in Hong Kong but also reinforces the region's position as a burgeoning hub for biopharmaceutical innovation. As the company embarks on this new chapter, it is poised to leverage its capital and technological expertise to drive further advancements in drug delivery systems, potentially influencing the trajectory of the global biopharmaceutical landscape. The implications of this IPO extend beyond METiS TechBio, signaling a robust appetite for innovative healthcare solutions and a commitment to harnessing AI for transformative impacts in medicine.